Nom du produit:5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde

IUPAC Name:5-(2-fluorophenyl)-1H-pyrrole-3-carbaldehyde

CAS:881674-56-2
Formule moléculaire:C11H8FNO
Pureté:95%+
Numéro de catalogue:CM198689
Poids moléculaire:189.19

Unité d'emballage Stock disponible Prix($) Quantité
CM198689-25g in stock IJȃ
CM198689-100g in stock ƈǪǙ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:881674-56-2
Formule moléculaire:C11H8FNO
Point de fusion:-
Code SMILES:O=CC1=CNC(C2=CC=CC=C2F)=C1
Densité:
Numéro de catalogue:CM198689
Poids moléculaire:189.19
Point d'ébullition:370.6±32.0°C at 760 mmHg
N° Mdl:MFCD11875867
Stockage:Keep in a tight container and store at 2°C~8°C

Category Infos

Pyrroles
Pyrrole is a five membered heterocyclic compound with the molecular formula of C4H5N. Pyrrole has a ring composed of four carbon atoms and one nitrogen atom. Pyrrole is easy to polymerize in the air. Pyrrole is the parent compound of many important biological substances (such as bile pigment, porphyrin and chlorophyll). Pyrrole scaffolds are widely used in biological and pharmaceutical fields. Pyrrole is a special heterocyclic scaffold, which exists in many natural products, drug molecules and pesticides, and has shown its application in materials science.
Pyrrole,Where to Buy Pyrroles-Chemenu
Pyrrole,Where to Buy Pyrroles
Pyrrole is a heterocyclic, aromatic, organic compound, a five-membered ring with the formula C 4H 4NH. It is a colorless volatile liquid that darkens readily upon exposure to air. Substituted derivatives are also called pyrroles, e.g., N-methylpyrrole.

Column Infos

Vonoprazan
Nov. 01, 2023, FDA has approved VOQUEZNA (vonoprazan) tablets, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of Erosive Esophagitis, also known as Erosive GERD (gastroesophageal reflux disease).
PCABs are a novel class of medicines that block acid secretion in the stomach, and VOQUEZNA is the first PCAB to be approved in the U.S. Vonoprazan has shown the potential to provide acid suppression that can achieve pH levels that are important in enhancing treatment effectiveness.